Polyclonal antibody stimulator(Aphton Corp.)(Polyclonal antibody stimulator(Aphton Corp.)) - 药物靶点：GAST_在研适应症：胰腺癌，胃癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗、结合疫苗

别名

Anti-gastrin 17 immunogen、Antigastrin 17、Gastrimmune

+ [9]

靶点

GAST

作用方式

抑制剂、刺激剂

作用机制

GAST抑制剂(促胃泌素17抑制剂)、免疫刺激剂

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病

在研适应症

胰腺癌胃癌

非在研适应症

大肠腺癌食管癌胃食管交界处恶性肿瘤+ [3]

原研机构

Aphton Corp.

在研机构

Aphton Corp.

非在研机构

Cancer Advances, Inc.

权益机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

16

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床试验

NCT00020787

/ Completed临床3期IIT

An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemotherapy For Advanced Disease (Stage IV)

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy and chemotherapy in treating patients who have metastatic or locally recurrent stomach cancer or esophageal cancer.

开始日期2001-07-01

申办/合作机构

Jonsson Comprehensive Cancer Center

NCT02118077

/ Completed临床3期

A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.

Compare the effect of G17DT with that of placebo on the survival of subjects with advanced pancreatic cancer.

开始日期2001-04-01

申办/合作机构

Cancer Advances, Inc.

NCT02118064

/ Completed临床2期

A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.

This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.

开始日期2001-03-01

申办/合作机构

Cancer Advances, Inc.

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的临床结果

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的转化医学

登录后查看更多信息

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的专利（医药）

登录后查看更多信息

2,649

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的文献（医药）

2025-12-01·Food chemistry. Molecular sciences

Effects of dietary prickly ash seeds supplementation on muscle development and volatile compounds of Hu sheep

Article

作者: Wu, Yi ; Ma, Youji ; Wang, Chunhui ; Li, Qiao ; Liu, Zilong ; Ma, Xueyi

Prickly ash seeds (PAS), a nutrient-rich by-product, show potential as a sustainable feed for Hu sheep. The current study aims to explore the effects of dietary supplementation with PAS on muscle development and volatile compounds of Hu sheep through multi-omics analysis. The increased muscle fiber diameter and cross-sectional area was associated with dietary supplementation with PAS compared with the CK group (P < 0.05). Transcriptome analysis showed that ACTC1, SERPINA3, COX2, MYBPH, FMOD, and KLHL34 were key differentially expressed genes (DEGs) involved in muscle growth and development, and played a role through oxidative phosphorylation, TCA cycle, fatty acid metabolism, and tryptophan metabolism. The combined analysis of transcriptome and volatile metabolomics showed that LEP, ADCY1, TMEM54, COX2, PCK1, and CPT1A may play an important regulatory role in the production of volatile compounds such as cetene, dodecanal, 2,6-dodecadien-1-al, palmitoleic acid, dodecanoic acid, ethyl ester by participating in lipid metabolism. In summary, PAS demonstrates promise for Hu sheep production, enhancing muscle development and influencing muscle flavor by modulating fatty acid metabolism-related genes.

2025-11-01·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Pillar[n]arenes versus cyclodextrins as supramolecular carriers for improved bioavailability: Idebenone as a model drug

Article

作者: Yeffet, Dina ; Hadar, Maya ; Saphier, Sigal ; Horin, Inbar ; Zafrani, Yossi ; Kaizerman-Kane, Dana ; Columbus, Ishay ; Smolkin, Boris ; Cohen, Yoram

The present study describes the ability of different water soluble pillararenes (PAs) to complex and solubilize Idebenone (IDE), as a model drug, and the results are compared to previously reported complexes of IDE with cyclodextrins (CDs). We show that P[5]As strongly bind IDE, with the CDs showing lower binding and P[6]As exhibiting the weakest binding. The differences between the weak and strong complexes reached above two orders of magnitude in the binding constants. The solubility-permeability interplay was then investigated to determine the best structures for potential improvement of bioavailability under different circumstances. For unsaturated solutions, using an in-vitro BBB permeability model, the highest permeability was obtained with the weakest complexes, demonstrating the solubility-permeability interplay whereby higher binding leads to lower permeability. However, when saturated solutions/suspensions were used, with the oral in-vitro permeapad® permeability model, stronger complexes led to higher permeation and drug flux. By comparing to cyclodextrins we show that PAs may be a significant addition to the CDs family, commonly used for bioavailability improvement in pharmaceutical applications.

2025-11-01·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

pH-Sensitive acrylic acid grafted Abelmoschus esculentus composite for sustained release of pantoprazole sodium

Article

作者: Ijaz, Bushra ; Aslam, Samina ; Ghumman, Shazia Akram ; Batool, Tahira ; Basharat, Maryam ; Anwar, Farooq ; Noreen, Sobia ; Ahmed, Nisar ; Aslam, Afeefa ; Munawar, Khurram Shahzad ; Batool, Fozia ; Alsader, Khadeeja Ali

The research presents a pH-sensitive acrylic acid-grafted hydrogel (graft composite) derived from Abelmoschus esculentus mucilage (AEM) to improve therapeutic outcomes in Crohn's disease and ulcerative colitis. The FT-IR spectroscopy, scanning electron microscopy (SEM), and X-ray diffraction (XRD) confirm successful grafting with a porous structure favorable for drug loading. Drug release studies showed slower PAS release under acidic conditions and faster release under alkaline conditions, mimicking the pH variations of the gastrointestinal tract. Release kinetics confirmed the Korsmeyer-Peppas model, exhibiting non-Fickian diffusion behavior, especially in the alkaline medium, with R² value ranging from 0.9874 to 0.9989. Biocompatibility assessments, including cytotoxicity, hemocompatibility, and acute oral toxicity tests, demonstrated that the graft composite is safe for use. In vivo studies confirmed an increase in the half-life of PAS from 1.119 to 4.395 h. This pH-sensitive delivery system offers a promising approach for the controlled, targeted release of PAS in the colon, enhancing therapeutic efficacy for patients with inflammatory bowel diseases. The successful development of this grafted composite represents a significant advancement in biocompatible, controlled drug delivery for gastrointestinal disorders.

1

项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的新闻（医药）

2023-02-28

·BioSpace

Cancer Advances, Inc. Announces Issuance of New U.S. Patent - February 28, 2023

DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S. Patent and Trademark Office has issued new patent No. 11,583,576, enhancing the Company’s intellectual property position for lead asset Polyclonal Antibody Stimulator (PAS) vaccine. The new patent titled “Compositions and Methods for Inducing Humoral and Cellular Immunities against Tumors and Cancer” covers a method for treating and/or preventing and/or inhibiting development of a tumor and/or a cancer associated with gastrin signaling in a subject. Gastrin mediated tumors include, but are not limited to, gastrointestinal cancers. The novel IP further covers methods for treatment of GI cancer by administering PAS followed by an immune checkpoint inhibitor. A related claim covers reduction in fibrosis associated with pancreatic cancer via the administration of this combination. “After more than six years of research, we are excited to have this patent issued. We have known that PAS can induce the development of antibodies to Gastrin, bringing Gastrin levels down and increasing survival times by 50% in GI clinical trials. With our research now demonstrating that PAS is able to alter the tumor microenvironment, it opens the door to many new opportunities to improve current treatment for GI cancer patients,” commented Lynda Sutton, President of Cancer Advances. The issued patent adds to the over one hundred granted global patents for PAS. Cancer Advances plans to seek approval for PAS in the treatment of gastric and pancreatic cancers. About Cancer Advances, Inc. Cancer Advances Inc. (Durham, NC) is a biotechnology company focused on impacting human health and preventing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team with over one hundred and twenty years of combined experience in drug development and commercialization experience. About Polyclonal Antibody Stimulator (PAS) Polyclonal Antibody Stimulator (PAS) vaccine is an immunomodulator potentially applicable in multiple cancer types including gastric, pancreatic, and colorectal. The vaccine is a peptide-conjugate that includes an N-terminal epitope of human gastrin-17 (G17) linked to carrier diphtheria toxoid. PAS has been studied in multiple clinical trials, in over 1,500 human subjects, and has demonstrated an excellent safety and tolerability profile. Cancer Advances exclusively owns PAS and is funding and managing all aspects of the PAS gastrin vaccine program. Contact Cancer Advances, Inc. E-mail: jwingen@canceradvances.com

疫苗免疫疗法

100 项与 Polyclonal antibody stimulator(Aphton Corp.) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB04914

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃癌	临床3期	美国	Cancer Advances, Inc.	2009-01-19
胰腺腺癌	临床3期	-	Cancer Advances, Inc.	2000-08-14
胰腺癌	临床3期	-	Aphton Corp.	-
食管癌	临床2期	-	Cancer Advances, Inc.	2000-08-01
胃食管交界处恶性肿瘤	临床2期	-	Cancer Advances, Inc.	2000-08-01
胃腺癌	临床2期	-	Cancer Advances, Inc.	1998-09-01
大肠腺癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01
转移性结直肠癌	临床2期	英国	Cancer Advances, Inc.	1993-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2006	临床3期	-	-	Gemcitabine + G17DT	憲窪構範衊淵鬱積繭獵(夢觸夢獵構壓鹽遞網築) = 構淵襯齋壓夢鹹鬱襯衊淵衊襯網壓鬱醖鏇齋選 (廠繭繭築糧積鏇範艱窪 )	-	2006-06-20
				Gemcitabine alone (placebo)	憲窪構範衊淵鬱積繭獵(夢觸夢獵構壓鹽遞網築) = 觸遞鹽繭鬱憲鬱艱憲窪淵衊襯網壓鬱醖鏇齋選 (廠繭繭築糧積鏇範艱窪 )
ASCO2004	N/A	晚期胰腺腺癌	154	G17DT	繭窪製憲窪壓築鹽願壓(遞願積膚遞夢壓觸繭遞) = 獵鹹積鏇獵製鬱蓋鹹壓憲艱膚糧齋鹽鬱壓襯網 (夢觸壓鬱鑰遞鹽艱積餘 )	积极	2004-07-15
				Placebo	繭窪製憲窪壓築鹽願壓(遞願積膚遞夢壓觸繭遞) = 繭壓襯夢範顧願窪壓鹽憲艱膚糧齋鹽鬱壓襯網 (夢觸壓鬱鑰遞鹽艱積餘 )